RxSight, Inc. (NASDAQ:RXST) Receives Average Recommendation of “Buy” from Brokerages

RxSight, Inc. (NASDAQ:RXSTGet Rating) has received a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $19.83.

A number of equities analysts have recently commented on RXST shares. Zacks Investment Research downgraded RxSight from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th. Needham & Company LLC began coverage on RxSight in a report on Friday, April 8th. They set a “buy” rating and a $18.00 price objective on the stock.

NASDAQ:RXST traded up $1.38 during mid-day trading on Friday, reaching $13.62. The company’s stock had a trading volume of 58,773 shares, compared to its average volume of 110,342. The company’s fifty day simple moving average is $12.24 and its two-hundred day simple moving average is $12.01. The company has a debt-to-equity ratio of 0.32, a current ratio of 15.12 and a quick ratio of 15.19. RxSight has a twelve month low of $8.80 and a twelve month high of $19.67. The stock has a market cap of $374.62 million and a P/E ratio of -2.50.

RxSight (NASDAQ:RXSTGet Rating) last released its quarterly earnings data on Tuesday, March 8th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.02. The company had revenue of $8.43 million for the quarter, compared to the consensus estimate of $8.40 million. RxSight had a negative return on equity of 251.55% and a negative net margin of 212.04%. Sell-side analysts expect that RxSight will post -2.79 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of RXST. RA Capital Management L.P. acquired a new position in shares of RxSight in the 3rd quarter worth approximately $38,679,000. Deerfield Management Company L.P. Series C acquired a new position in shares of RxSight in the 3rd quarter worth approximately $11,403,000. BlackRock Inc. grew its position in shares of RxSight by 86.0% in the 1st quarter. BlackRock Inc. now owns 735,589 shares of the company’s stock worth $9,106,000 after acquiring an additional 340,091 shares in the last quarter. Vanguard Group Inc. grew its position in shares of RxSight by 89.1% in the 1st quarter. Vanguard Group Inc. now owns 638,813 shares of the company’s stock worth $7,908,000 after acquiring an additional 301,055 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of RxSight in the 3rd quarter worth approximately $4,175,000. Institutional investors own 31.57% of the company’s stock.

About RxSight (Get Rating)

RxSight, Inc, a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Featured Articles

Analyst Recommendations for RxSight (NASDAQ:RXST)

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.